ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0026

Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin

Michael Newton1, Aanya Mohan2, Tareq Hanna3, Dana Orange4, John Varga2 and Tristan Maerz2, 1University of Michigan, South Lyon, MI, 2University of Michigan, Ann Arbor, MI, 3Wayne State University, Detroit, MI, 4The Rockefeller University, New York, NY

Meeting: ACR Convergence 2024

Keywords: Bioinformatics, Fibroblasts, Synovial, Fibrosing syndromes, Osteoarthritis, Scleroderma, Systemic

  • Tweet
  • Email
  • Print
Session Information

Date: Saturday, November 16, 2024

Title: Osteoarthritis & Joint Biology – Basic Science Poster

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Synovial fibrosis is a hallmark of osteoarthritis (OA) and a clinical correlate to joint pain. Fibrosis of skin, lungs and other organs is the hallmark of systemic sclerosis (SSc). Both OA synovium and SSc skin exhibit extracellular matrix changes, ectopic chondrogenesis/mineralization, nociceptive sensitization, and inflammatory infiltrates, but studies directly comparing these conditions are lacking. We utilized human single cell RNA sequencing (scRNAseq) data to interrogate the nature and extent of conserved fibroblast signaling in OA synovium and SSc skin, using idiopathic pulmonary fibrosis (IPF) as a comparison of bona fide fibrosis.

Methods: An integrative analysis utilized publicly available scRNAseq datasets from human OA synovium and SSc skin (Fig 1ABD). Major cell types were clustered and identified (Fig 1C). Fibroblasts from OA and SSc datasets were re-integrated into a joint data object and subclustered into 9 populations with distinct gene signatures (Fig 1EF). Subclusters were analyzed to determine relative abundance, cluster-specific gene markers, and functional roles (via gene ontology, GO). To define a “fibrotic reference gene set”, human lung scRNAseq data of healthy and IPF patients (N=6) was obtained (Fig 3AB) and differential gene expression was assessed between healthy and IPF fibroblasts (Fig 3C).

Results: Five fibroblast clusters (1,2,3,4,5) were substantially conserved in OA and SSc and participated in shared, disease-relevant GO terms (matrix deposition, immune/inflammatory signaling, Fig 2A-D). One cluster (6) was unique to OA (synovial lining fibroblasts); 3 clusters (7,8,9) were unique to SSc (Fig 2ABD). Despite being transcriptionally distinct, OA- and SSc- specific clusters both express genes related to shared, disease-relevant GO terms (Wnt signaling, neuromodulation, angiogenesis, Fig. 2E). A fibrotic reference gene set was identified (Fig 3C) comprising 3,899 genes differentially expressed between IPF and healthy lung fibroblasts, involved in fibrosis-relevant GO terms (collagen metabolism, chondrogenesis, mineralization, neuromodulation, Fig 3D). The top 50 genes overexpressed in IPF were clustered into 3 distinct modules – within OA/SSc fibroblasts, these modules were primarily expressed within 3 subclusters (Fig 3E), with strong module 1 expression in clusters 3 (SFRP2+) and 9 (TNMD+), module 2 in cluster 3 (SFRP2+), and module 3 in cluster 6 (PRG4+). Across all 481 genes strongly overexpressed in IPF (Padj < 0.05, log2fc > 1), the highest expression in OA/SSc fibroblasts occurred in a distinct subset of cells expressing COL8A1, which has been linked with cardiac fibrosis, along with myofibrotic markers (Fig 3F).

Conclusion: OA synovium and SSc skin share several transcriptionally-distinct fibroblast subsets related to matrix deposition and immunomodulation, suggesting these fibrosis-relevant functions are well-conserved between the two conditions. OA and SSc fibroblasts both express a fibrotic gene signature consistent with bona fide fibrotic disease (e.g. IPF). This expression is largely confined to specific fibroblast subsets, establishing potential therapeutic avenues targeting these subpopulations for fibrosis treatment.

Supporting image 1

Figure 1. (A) Clustering of scRNAseq data in OA synovium and (B) SSc skin samples. (C) Annotation of major cell types via established markers enabled accurate isolation of fibroblasts from other cells. (D) The integrated fibroblast object was composed of similar numbers of OA and SSc fibroblasts. (E) Subclustering of fibroblasts revealed the presence of transcriptionally distinct (F) fibroblast subsets.

Supporting image 2

Figure 2. (A) Fibroblast subclustering UMAP and (B) cell counts, split by disease. (C) GO terms for subclusters shared between OA and SSc. (D) Differential Abundance analysis of fibroblast subclusters. (E) GO terms shared between OA- and SSc-specific subclusters.

Supporting image 3

Figure 3. (A) Clustering of fibroblasts from healthy and IPF lung tissue demonstrated (B) marked enrichment of fibroblasts in IPF compared to healthy tissue. (C) DE analysis between healthy and IPF fibroblasts revealed a fibrotic signature including 3,899 differentially-regulated genes (D) GO functions relevant to fibrosis. (E) Mapping the 50 most positively-expressed fibrotic genes onto OA/SSc fibroblasts revealed 3 distinct gene modules associated with both conserved and disease-specific subclusters. (F) Mapping all highly upregulated fibrotic genes (Padj < 0.05, log2 fold change > 1) onto OA/SSc fibroblasts revealed strong expression in a specific subset of fibroblasts within cluster 3 which selectively express COL8A1, along with other markers of myofibroblasts.


Disclosures: M. Newton: None; A. Mohan: None; T. Hanna: None; D. Orange: AstraZeneca, 2, Pfizer, 2; J. Varga: None; T. Maerz: None.

To cite this abstract in AMA style:

Newton M, Mohan A, Hanna T, Orange D, Varga J, Maerz T. Conserved Pro-Fibrotic Fibroblast Signatures in Osteoarthritis Synovium and Systemic Sclerosis Skin [abstract]. Arthritis Rheumatol. 2024; 76 (suppl 9). https://acrabstracts.org/abstract/conserved-pro-fibrotic-fibroblast-signatures-in-osteoarthritis-synovium-and-systemic-sclerosis-skin/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2024

ACR Meeting Abstracts - https://acrabstracts.org/abstract/conserved-pro-fibrotic-fibroblast-signatures-in-osteoarthritis-synovium-and-systemic-sclerosis-skin/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology